Troxipide
Title: Troxipide
CAS Registry Number: 99777-81-8
CAS Name: 3,4,5-Trimethoxy-N-3-piperidinylbenzamide
Additional Names: 3-(3,4,5-trimethoxybenzamido)piperidine
Manufacturers' Codes: KU-54
Trademarks: Aplace (Kyorin)
Molecular Formula: C15H22N2O4
Molecular Weight: 294.35
Percent Composition: C 61.21%, H 7.53%, N 9.52%, O 21.74%
Literature References: Prepn: BE 736840; T. Irikura et al., US 3647805 (1969, 1972 both to Kyorin). Anti-ulcer activity: T. Irikura, K. Kasuga, J. Med. Chem. 14, 357 (1971). Pharmacokinetics in man: T. Irikura et al., Iyakuhin Kenkyu 12, 971 (1981), C.A. 96, 79377s (1982). Effect on gastric mucosa in rats: Y. Abe et al., Nippon Yakurigaku Zasshi 83, 317 (1984), C.A. 101, 456g (1984); on glucosamine synthetase: Y. Abe et al., Oyo Yakuri 27, 521 (1984), C.A. 101, 17001c (1984). Metabolism in rats: K. Tagaki et al., ibid. 1151, C.A. 101, 103555t (1984); K. Tagaki, K. Endo, ibid. 1167, C.A. 101, 103556u (1984). Toxicity: T. Irikura et al., Kiso to Rinsho 12, 3422 (1978).
Properties: Needles from acetonitrile, mp 179-181.5°. Sol in ethanol. LD50 in male, female rats, male, female mice (mg/kg): 500, 2100, 2200, 2000 orally; >4150, >4150, 1600, 1550 s.c.; 340, 340, 300, 305 i.p. (Irikura, 1978).
Melting point: mp 179-181.5°
Toxicity data: LD50 in male, female rats, male, female mice (mg/kg): 500, 2100, 2200, 2000 orally; >4150, >4150, 1600, 1550 s.c.; 340, 340, 300, 305 i.p.
 
Derivative Type: Hydrochloride hemihydrate
Molecular Formula: C15H22N2O4.HCl.½H2O
Molecular Weight: 339.81
Percent Composition: C 53.02%, H 7.12%, N 8.24%, O 21.19%, Cl 10.43%
Properties: Needles from acetonitrile, mp 206-209°. Sol in ethanol.
Melting point: mp 206-209°
 
Therap-Cat: Antiulcerative.
Keywords: Antiulcerative; Cytoprotectant (Gastric).

Others monographs:
2,4,6-TrichloroanisoleInterleukin-5Isobutyl FormateAcetoxime
Mercuric BromideHerrmann-Beller CatalystIsobutyl SulfideTromethamine
1,8-NaphthalenediaminePyrimidineMethyl ChlorocarbonateChlorpheniramine
PhenylhydroxylamineMethylhydrazineCetyl PalmitateJalap
©2016 DrugLead US FDA&EMEA